Shares in Johnson & Johnson slid around 10% on Friday after a Reuters article claimed the company had known for decades about asbestos in talcum powder products.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh